Cytek Biosciences Achieves 40-Color Panel from a Single Sample with New Flow System
The cytometry system is available with up to five lasers to analyze up to 40 markers in one sample.
Cytek Biosciences, a flow cytometry instrumentation provider based in Fremont, CA, has developed and demonstrated a high-quality 40-color panel from a single sample using the Cytek Aurora advanced flow cytometry system.
The device uses various patent-pending technologies and allows users to combine their markers in one sample and achieve high resolution for each individual marker, according to a Sept. 25, 2019 press release. The cytometry system is available with up to five lasers to analyze up to 40 markers in one sample and provides users with flexible dye choices, the power to extract sample autofluorescence, intuitive workflows, and the ability to extract multiplexed high-quality data from a single test.
“As the flow cytometry market continues to expand rapidly and reach an estimated $8.92 billion globally by 2026, we fully expect that the Aurora will become a large, powerful, and capable presence in the market,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences, in the press release. “We are committed to addressing the lack of access to advanced scientific instrumentation and giving scientists the tools they need to take their fields to the next level. High-quality 40-color data makes in-depth insights and statistically powerful numbers from rare sample populations possible-and accelerates the pace of scientific discovery.”
Source: Cytek Biosciences
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
